Current Report Filing (8-k)
May 10 2018 - 7:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
May 8, 2018
ONCOSEC
MEDICAL INCORPORATED
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
5820
Nancy Ridge Drive
|
|
|
San
Diego, California
|
|
92121
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(855) 662-6732
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01. Other Events.
On May 8, 2018, OncoSec
Medical Incorporated (“OncoSec”) issued a press release announcing the Clinical Trial Collaboration and Supply Agreement
(“Agreement”) with Merck (known as MSD outside the United States and Canada). A copy of the press release is being
furnished as Exhibit 99.1 to this Current Report.
Pursuant to the Agreement,
OncoSec and Merck will evaluate the combination of OncoSec's ImmunoPulse® IL-12 with Merck's anti-PD-1 therapy KEYTRUDA®
(pembrolizumab) in a Phase 2 clinical trial. Under the Agreement, OncoSec will sponsor and fund the Phase 2 study of ImmunoPulse®
IL-12 in combination with KEYTRUDA® in patients to evaluate the safety and efficacy of the combination in patients with inoperable
locally advanced or metastatic triple negative breast cancer (TNBC) who have previously failed at least one systemic chemotherapy
or immunotherapy.
The study will be a
Phase 2, Simon 2-stage minimax design, non-comparative, open-label, single-arm, multicenter study. The study is planned to enroll
approximately 25 subjects (15 subjects in Stage 1 and, if appropriate, another 10 subjects in Stage 2) and the trial is expected
to commence in mid-2018.
The information in Item 8.01 of this Current Report, including the attached Exhibit 99.1 furnished herewith,
is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 8.01
of this Current Report, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to this Current Report in such
a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED
|
|
|
|
Dated:
May 10, 2018
|
By:
|
/s/
Daniel J. O’Connor
|
|
|
Daniel
J. O’Connor
|
|
|
President
& Chief Executive Officer
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024